ArticlePloS one2023
BCR-Net: A deep learning framework to predict breast cancer recurrence from histopathology images.
Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Pretreatment Prediction of Tumor Recurrence in Breast Cancer After Neoadjuvant Systemic Therapy Using Machine Learning With Clinical and CT Radiomics Features.The Kaohsiung journal of medical sciences · 2026Article
- Article
- GenoGlyph: Pan-cancer genomic mutation inference and risk stratification from diagnostic histopathology slides.Research square · 2026Article
- Deep learning on histopathological images to predict breast cancer recurrence risk and chemotherapy benefit: a multicentre, model development and validation study.The Lancet. Oncology · 2026Article
- Learning the Language of Histopathology Images reveals Prognostic Subgroups in Invasive Lung Adenocarcinoma Patients.Research square · 2026Article
- Deep learning-enabled multiphoton microscopy predicts colorectal cancer recurrence from routine FFPE specimens.NPJ digital medicine · 2025Article
- HistoChat: Instruction-tuning multimodal vision language assistant for colorectal histopathology on limited data.Patterns (New York, N.Y.) · 2025Article
- Deep learning assessment of metastatic relapse risk from digitized breast cancer histological slides.Nature communications · 2025Article
- Article
- Deep learning-based interpretable prediction of recurrence of diffuse large B-cell lymphoma.BJC reports · 2025Article
- Deep Learning on Histopathological Images to Predict Breast Cancer Recurrence Risk and Chemotherapy Benefit.medRxiv : the preprint server for health sciences · 2025Article
- Multimodal histopathologic models stratify hormone receptor-positive early breast cancer.Nature communications · 2025Article
- Harnessing artificial intelligence for predicting breast cancer recurrence: a systematic review of clinical and imaging data.Discover oncology · 2025Review
- TopoTxR: A topology-guided deep convolutional network for breast parenchyma learning on DCE-MRIs.Medical image analysis · 2025Article
- Current status and prospects of artificial intelligence in breast cancer pathology: convolutional neural networks to prospective Vision Transformers.International journal of clinical oncology · 2024Review
- Predicting Breast Cancer Relapse from Histopathological Images with Ensemble Machine Learning Models.Current oncology (Toronto, Ont.) · 2024Article
- Deep Learning Model for Predicting Lung Adenocarcinoma Recurrence from Whole Slide Images.Cancers · 2024Article
- Translating prognostic quantification of c-MYC and BCL2 from tissue microarrays to whole slide images in diffuse large B-cell lymphoma using deep learning.Diagnostic pathology · 2024Article
- Correction: BCR-Net: A deep learning framework to predict breast cancer recurrence from histopathology images.PloS one · 2024Article
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is the most common malignancy in women, with over 40,000 deaths annually in the United States alone. Clinicians often rely on the breast cancer recurrence score, Oncotype DX (ODX), for risk stratification of breast cancer patients, by using ODX as a guide for personalized therapy. However, ODX and similar gene assays are expensive, time-consuming, and tissue destructive. Therefore, developing an AI-based ODX prediction model that identifies patients who will benefit from chemotherapy in the same way that ODX does would give a low-cost alternative to the genomic test. To overcome this problem, we developed a deep learning framework, Breast Cancer Recurrence Network (BCR-Net), which automatically predicts ODX recurrence risk from histopathology slides. Our proposed framework has two steps. First, it intelligently samples discriminative features from whole-slide histopathology images of breast cancer patients. Then, it automatically weights all features through a multiple instance learning model to predict the recurrence score at the slide level. On a dataset of H&E and Ki67 breast cancer resection whole slides images (WSIs) from 99 anonymized patients, the proposed framework achieved an overall AUC of 0.775 (68.9% and 71.1% accuracies for low and high risk) on H&E WSIs and overall AUC of 0.811 (80.8% and 79.2% accuracies for low and high risk) on Ki67 WSIs of breast cancer patients. Our findings provide strong evidence for automatically risk-stratify patients with a high degree of confidence. Our experiments reveal that the BCR-Net outperforms the state-of-the-art WSI classification models. Moreover, BCR-Net is highly efficient with low computational needs, making it practical to deploy in limited computational settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.